BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29188580)

  • 21. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
    Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of efficacy of first-line administration of generic dasatinib or imatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia treated by hematopoietic stem cell transplantation].
    Yang F; Cai WZ; Huang XW; Xue SL; Fu CC; Tang XW; Sun AN; Wu DP; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):661-667. PubMed ID: 30180468
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
    Jabbour E; Haddad FG; Short NJ; Kantarjian H
    JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
    Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
    Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?
    Litzow MR
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):345-350. PubMed ID: 27890258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ohno R
    Curr Oncol Rep; 2008 Sep; 10(5):379-87. PubMed ID: 18706265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee KH; Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Kim WK; Lee JS; Seo EJ; Jang S; Park CJ; Chi HS
    Leukemia; 2005 Sep; 19(9):1509-16. PubMed ID: 16034462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
    Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
    Fujisawa S; Mizuta S; Akiyama H; Ueda Y; Aoyama Y; Hatta Y; Kakihana K; Dobashi N; Sugiura I; Onishi Y; Maeda T; Imai K; Ohtake S; Miyazaki Y; Ohnishi K; Matsuo K; Naoe T
    Am J Hematol; 2017 Apr; 92(4):367-374. PubMed ID: 28103625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy.
    Wu KH; Wu HP; Weng T; Peng CT; Chao YH
    Curr Oncol; 2015 Aug; 22(4):303-6. PubMed ID: 26300669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sustained molecular remission with a tyrosine kinase inhibitor alone for seven months in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Takahashi T; Shigeoka T; Suzukawa M; Ishido A; Tominaga T
    Rinsho Ketsueki; 2013 Feb; 54(2):210-3. PubMed ID: 23470829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.
    Thomas DA
    Hematology Am Soc Hematol Educ Program; 2007; ():435-43. PubMed ID: 18024662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yamada K; Yasui M; Kondo O; Sato M; Sawada A; Kawa K; Inoue M
    Pediatr Blood Cancer; 2013 Aug; 60(8):E60-2. PubMed ID: 23468187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical analysis of adult Philadelphia chromosome-positive acute lymphoblastic leukemia with p16 gene deletion].
    He BL; Xu N; Li YL; Pan CY; Cao R; Liao LB; Yin CX; Lan YQ; Lu ZY; Huang JX; Zhou HS; Liu QF; Liu XL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):204-209. PubMed ID: 28395443
    [No Abstract]   [Full Text] [Related]  

  • 38. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
    Cai B; Gao CJ; Li HH; Bo J; Huang WR; Gao L; Sun JF; Ding Y; Wang LL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):173-6. PubMed ID: 20137141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
    Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.